bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S2 from Prediagnostic Hormone Levels and Risk of Testicular Germ Cell Tumors: A Nested Case–Control Study in the Janus Serum Bank
Authors: Wu Zeni , Trabert Britton , Guillemette Chantal , Caron Patrick , Bradwin Gary , Graubard Barry I. , Weiderpass Elisabete , Ursin Giske , Langseth Hilde , McGlynn Katherine A.
Published: November 2023

Supplementary Table S2 show the Pearson correlation matrix of hormones
Supplementary Table S1 from Prediagnostic Hormone Levels and Risk of Testicular Germ Cell Tumors: A Nested Case–Control Study in the Janus Serum Bank
Authors: Wu Zeni , Trabert Britton , Guillemette Chantal , Caron Patrick , Bradwin Gary , Graubard Barry I. , Weiderpass Elisabete , Ursin Giske , Langseth Hilde , McGlynn Katherine A.
Published: November 2023

Supplementary Table S1 shows the percent of samples above LLOD, their Cs and ICC for the hormone measurements.
Supplementary Table 1 from Sources of Disparities in Surveillance Mammography Performance and Risk-Guided Recommendations for Supplemental Breast Imaging: A Simulation Study
Authors: Hubbard Rebecca A. , Pujol Toyya A. , Alhajjar Elie , Edoh Kossi , Martin Melissa L.
Published: November 2023

Supplementary Table 1. Distributional assumptions and input parameter values for simulations. Model 1 includes no race and ethnicity variation, Model 2 includes variation in primary cancer and treatment characteristics by race and ethnicity, Model 3 includes variation in SDOH by race and ethnicity, Models 4 and 5 include variation in primary cancer and treatment characteristics as well as SDOH by race and ethnicity.}
Supplementary Methods 1 from Sources of Disparities in Surveillance Mammography Performance and Risk-Guided Recommendations for Supplemental Breast Imaging: A Simulation Study
Authors: Hubbard Rebecca A. , Pujol Toyya A. , Alhajjar Elie , Edoh Kossi , Martin Melissa L.
Published: November 2023

Supplementary Methods 1: Simulation study design description
Supplementary Table S4 from Reproductive Factors in the Risk of Bladder Cancer and Upper Urinary Tract Cancer: The Japan Public Health Center-Based Prospective Study
Authors: Minami Tetsuji , Inoue Manami , Yamaji Taiki , Iwasaki Motoki , Tsugane Shoichiro , Sawada Norie
Published: November 2023

Supplementary Table S4: HRs and 95% CI of UC according to reproductive factors among never-smoker and no estrogen-dependent disease women.
Supplemental Table 1 from Administrative Burden Associated with Cost-Related Delays in Care in U.S. Cancer Patients
Authors: Doherty Meredith , Thom Bridgette , Gardner Daniel S.
Published: November 2023

Supplemental Table 1 shows the twopart analysis of the relationship between time since diagnosis (IV) and cost-related nonadherence (DV1) and administrative burden (DV2)
Data from Impact of BMI on Prevalence of Dense Breasts by Race and Ethnicity
Authors: Kerlikowske Karla , Bissell Michael C. S. , Sprague Brian L. , Tice Jeffrey A. , Tossas Katherine Y. , Bowles Erin J. A. , Ho Thao-Quyen H. , Keegan Theresa H. M. , Miglioretti Diana L.
Published: November 2023

AbstractBackground:
Density notification laws require notifying women of dense breasts with dense breast prevalence varying by race/ethnicity. We evaluated whether differences in body mass index (BMI) account for differences in dense breasts prevalence by race/ethnicity.
Methods:
Prevalence of dense breasts (heterogeneously or extremely dense) according to Breast Imaging Reporting and Data System and obesity (BMI > 30 kg/m2) were estimated from 2,667,207 mammography examinations among 866,033 women in the Breast Cancer Surveillance Consortium (BCSC) from January 2005 through April 2021. Prevalence ratios (PR) for dense breasts relative to overall prevalence by race/ethnicity were estimated by standardizing race/ethnicity prevalence in the BCSC to the 2020 U.S. population, and adjusting for age, menopausal status, and BMI using logistic regression.
Results:
Dense breasts were most prevalent among Asian women (66.0%) followed by non-Hispanic/Latina (NH) White (45.5%), Hispanic/Latina (45.3%), and NH Black (37.0%) women. Obesity was most prevalent in Black women (58.4%) followed by Hispanic/Latina (39.3%), NH White (30.6%), and Asian (8.5%) women. The adjusted prevalence of dense breasts was 19% higher [PR = 1.19; 95% confidence interval (CI), 1.19–1.20] in Asian women, 8% higher (PR = 1.08; 95% CI, 1.07–1.08) in Black women, the same in Hispanic/Latina women (PR = 1.00; 95% CI, 0.99–1.01), and 4% lower (PR = 0.96; 95% CI, 0.96–0.97) in NH White women relative to the overall prevalence.
Conclusions:
Clinically important differences in breast density prevalence are present across racial/ethnic groups after accounting for age, menopausal status, and BMI.
Impact:
If breast density is the sole criterion used to notify women of dense breasts and discuss supplemental screening it may result in implementing inequitable screening strategies across racial/ethnic groups.

See related In the Spotlight, p. 1479
Data from Cigarette and Alternative Tobacco Product Use among Adult Cancer Survivors Enrolled in 9 ECOG-ACRIN Clinical Trials
Authors: Streck Joanna M. , Lee Ju-Whei , Walter Angela Wangari , Rosen Rachel L. , Gareen Ilana F. , Kircher Sheetal Mehta , Herman Benjamin A. , Carlos Ruth C. , Kumar Shaji , Mayer Ingrid A. , Saba Nabil F. , Fenske Timothy S. , Neal Joel W. , Atkins Michael B. , Hodi F. Stephen , Kyriakopoulos Christos E. , Tempany Clare , Shanafelt Tait D. , Wagner Lynne I. , Land Stephanie R. , Park Elyse R. , Ostroff Jamie S.
Published: November 2023

AbstractBackground:
While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known about ATP use patterns in cancer survivors enrolled in clinical trials. We investigated prevalence of tobacco product use, and factors associated with past 30-day use, among patients with cancer in national trials.
Methods:
Cancer survivors (N = 756) enrolled in 9 ECOG-ACRIN clinical trials (2017–2021) completed a modified Cancer Patient Tobacco Use Questionnaire (C-TUQ) which assessed baseline cigarette and ATP use since cancer diagnosis and in the past 30 days.
Results:
Patients were on average 59 years old, 70% male, and the mean time since cancer diagnosis was 26 months. Since diagnosis, cigarettes (21%) were the most common tobacco product used, followed by smokeless tobacco use (5%), cigars (4%), and e-cigarettes (2%). In the past 30 days, 12% of patients reported smoking cigarettes, 4% cigars, 4% using smokeless tobacco, and 2% e-cigarettes. Since cancer diagnosis, 5.5% of the sample reported multiple tobacco product use, and 3.0% reported multiple product use in the past 30 days. Males (vs. females; OR 4.33; P = 0 < 0.01) and individuals not living with another person who smokes (vs. living with; OR, 8.07; P = 0 < 0.01) were more likely to use ATPs only versus cigarettes only in the past 30 days.
Conclusions:
Among patients with cancer, cigarettes were the most prevalent tobacco product reported.
Impact:
Regardless, ATPs and multiple tobacco product use should be routinely assessed in cancer care settings.
Data from Effectiveness and Cost of an Enhanced Mailed Fecal Test Outreach Colorectal Cancer Screening Program: Findings from the PROMPT Stepped-Wedge Trial
Authors: Coronado Gloria D. , Nyongesa Denis B. , Escaron Anne L. , Petrik Amanda F. , Thompson Jamie H. , Smith Dave , Davis Melinda M. , Schneider Jennifer L. , Rivelli Jennifer S. , Laguna Tanya , Leo Michael C.
Published: November 2023

AbstractBackground:
Mailed fecal immunochemical test (FIT) outreach can improve colorectal cancer screening rates, yet little is known about how to optimize these programs for effectiveness and cost.
Methods:
PROMPT was a pragmatic, stepped-wedge, cluster-randomized effectiveness trial of mailed FIT outreach. Participants in the standard condition were mailed a FIT and received live telephone reminders to return it. Participants in the enhanced condition also received a tailored advance notification (text message or live phone call) and two automated phone call reminders. The primary outcome was 6-month FIT completion; secondary outcomes were any colorectal cancer screening completion at 6 months, implementation, and program costs.
Results:
The study included 27,585 participants (80% ages 50–64, 82% Hispanic/Latino; 68% preferred Spanish). A higher proportion of enhanced participants completed FIT at 6 months than standard participants, both in intention-to-treat [+2.8%, 95% confidence interval (CI; 0.4–5.2)] and per-protocol [limited to individuals who were reached; +16.9%, 95% CI (12.3–20.3)] analyses. Text messages and automated calls were successfully delivered to 91% to 100% of participants. The per-patient cost for standard mailed FIT was $10.84. The enhanced program's text message plus automated call reminder cost an additional $0.66; live phone calls plus an automated call reminder cost an additional $10.82 per patient.
Conclusions:
Adding advance notifications and automated calls to a standard mailed FIT program boosted 6-month FIT completion rates at a small additional per-patient cost.
Impact:
Enhancements to mailed FIT outreach can improve colorectal cancer screening participation. Future research might test the addition of educational video messaging for screening-naïve adults.
Data from Inference on the Genetic Architecture of Breast Cancer Risk
Authors: Yasui Yutaka , Letsou William , Wang Fan , Im Cindy , Sapkota Yadav , Wang Zhaoming , Salehabadi Sedigheh Mirzaei , Baedke Jessica L. , Moon Won Jong , Liu Qi , Robison Leslie L. , Martinez Jose Miguel
Published: November 2023

AbstractBackground:
What are the major determinants of women's breast cancer risk? Rare mutations such as those in the BRCA1/2 genes, polygenic scores of common alleles identified by genome-wide association studies, or nongenetic factors?
Methods:
The population-based Nordic Twin Study of Cancer, with 3,933 breast cancer cases among 21,054 monozygotic (MZ) and 30,939 dizygotic (DZ) female twin pairs, provides three key clues to this question: (i) the average lifetime risk, approximately 8%, does not differ by twin zygosity; (ii) the mean time interval between diagnoses when both twins develop disease (i.e., disease concordance) also does not differ by zygosity; but, (iii) conditioning on one twin having developed disease, the incidence rate in the co-twin is approximately 1% per year if the pair is MZ and 0.5% per year if DZ.
Results:
Assuming that nongenetic risk factors are shared similarly between twins regardless of zygosity, we can draw two conclusions from (i) to (iii).
Conclusions:
First, (i) and (iii) imply that the chief determinant of risk is in the germline DNA, because the conditional incidence rate is several-fold higher than the average risk (8% lifetime) in MZ twins but only half as much in DZ twins. Second, the seeming inconsistency between the two-fold conditional incidence rate (iii) and the equality of the mean inter-twin disease intervals in disease concordance (ii) can be resolved if the risk factors in the germline DNA are rare variants, not common variants.
Impact:
This paper details simple deductive reasoning for these conclusions and draws a critical inference regarding breast cancer etiology.

See related In the Spotlight, p. 1477
Data from Assessing a Polygenic Risk Score for Lung Cancer Susceptibility in Non-Hispanic White and Black Populations
Authors: Trendowski Matthew R. , Lusk Christine M. , Wenzlaff Angela S. , Neslund-Dudas Christine , Gadgeel Shirish M. , Soubani Ayman O. , Schwartz Ann G.
Published: November 2023

AbstractBackground:
Polygenic risk scores (PRS) have become an increasingly popular approach to evaluate cancer susceptibility, but have not adequately represented Black populations in model development.
Methods:
We used a previously published lung cancer PRS on the basis of 80 SNPs associated with lung cancer risk in the OncoArray cohort and validated in UK Biobank. The PRS was evaluated for association with lung cancer risk adjusting for age, sex, total pack-years, family history of lung cancer, history of chronic obstructive pulmonary disease, and the top five principal components for genetic ancestry.
Results:
Among the 80 PRS SNPs included in the score, 14 were significantly associated with lung cancer risk (P < 0.05) in INHALE White participants, while there were no significant SNPs among INHALE Black participants. After adjusting for covariates, the PRS was significantly associated with risk in Whites (continuous score P = 0.007), but not in Blacks (continuous score P = 0.88). The PRS remained a statistically significant predictor of lung cancer risk in Whites ineligible for lung cancer screening under current U.S. Preventive Services Task Force guidelines (P = 0.02).
Conclusions:
Using a previously validated PRS, we did find some predictive ability for lung cancer in INHALE White participants beyond traditional risk factors. However, this effect was not observed in Black participants, indicating the need to develop and validate ancestry-specific lung cancer risk models.
Impact:
While a previously published lung cancer PRS was able to stratify White participants into different levels of risk, the model was not predictive in Blacks. Our findings highlight the need to develop and validate ancestry-specific lung cancer risk models.
Data from Epidemiology of Oral Human Papillomavirus Infection among Diverse Chinese Adults in Typical Areas of China: Findings from the DLCC Study
Authors: Zhu Yingying , He Huijing , Zhu Xiaoli , Hu Yaoda , Yu Shuting , Diao Wenwen , Li Shuguang , Shan Guangliang , Chen Xingming
Published: November 2023

AbstractBackground:
Human papillomavirus (HPV) infection is a predominant cause of oropharyngeal squamous cell carcinoma. However, there is limited knowledge about the epidemiology of oral HPV infections among adults in China.
Methods:
We collected data from a prospective cohort that enrolled participants in Mainland China. A total of 9,867 participants ages at least 20 years provided oral swab specimens in typical areas of China (Hebei and Guangdong provinces) in 2021. HPV DNA in oral exfoliated cells was tested using nested PCR and sequencing. Prevalence among subpopulations was compared. Multivariable logistic regression models were employed to assess possible factors influencing oral HPV infection.
Results:
The overall prevalence of oral HPV infection was 3.0% [95% confidence interval (CI): 2.68–3.36]. Among those infected, 1.3% (1.08–1.53) were infected with high-risk HPV types. Men had a higher age-standardized HPV infection prevalence (3.6%, 2.96–4.29) compared with their female counterparts (2.7%, 2.35–3.12). People in Hebei had a higher age- and sex-standardized prevalence (4.1%, 3.50–4.70) than those in Guangdong (2.2%, 1.80–2.56). Generally, men (OR and 95% CI: 1.42, 1.09–1.85) and people in Hebei (2.01, 1.53–2.65) had higher odds of any type of HPV infection. In addition, people living in urban areas had a 2.15-fold (1.43–3.26) higher odds of high-risk HPV infection.
Conclusions:
This study reveals a low prevalence of oral HPV infection with significant geographic and sex differences among Chinese population.
Impact:
This is the first study to report the epidemiologic characteristics of oral HPV infection among Chinese adults in diverse geographic areas with large sample size.
Data from Lifetime Body Weight Trajectories and Risk of Renal Cell Cancer: A Large U.S. Prospective Cohort Study
Authors: Deng Zhengyi , Hajihosseini Morteza , Moore Justin X. , Khan Saira , Graff Rebecca E. , Bondy Melissa L. , Chung Benjamin I. , Langston Marvin E.
Published: November 2023

AbstractBackground:
Body mass index (BMI) is a known risk factor for renal cell cancer (RCC), but data are limited as to the effect of lifetime exposure to excess body weight.
Methods:
Using the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (N = 138,614, 527 incident RCCs), we identified several anthropometric measures to capture the lifetime BMI patterns: (i) BMI at specific ages; (ii) adulthood BMI trajectories; (iii) cumulative exposure to overweight/obesity denoted as weighted years of living overweight/obese (WYO); and (iv) weight change during each age span. We conducted multivariable Cox model to quantify the association between each anthropometric metric and incident RCC.
Results:
A higher BMI at ages 20 and 50 and at baseline was associated with a greater hazard of RCC. Compared with individuals who retained normal BMI throughout adulthood, we observed an increased hazard of RCC for BMI trajectory of progressing from normal BMI to overweight [HR, 1.49; 95% confidence interval (CI), 1.19–1.87], from normal BMI to obesity (HR, 2.22; 95% CI, 1.70–2.90), and from overweight to obesity (HR, 2.78; 95% CI, 1.81–4.27). Compared with individuals who were never overweight (WYO = 0), elevated HRs were observed among individuals who experienced low (HR, 1.31; 95% CI, 0.99–1.74), medium (HR, 1.57; 95% CI, 1.20–2.05), and high (HR, 2.10; 95% CI, 1.62–2.72) WYO tertile. Weight gain of ≥10 kg was associated with increased RCC incidence for each age span.
Conclusions:
Across the lifespan, being overweight/obese, weight gain, and higher cumulative exposure to excess weight were all associated with increased RCC risk.
Impact:
It is important to avoid weight gain and assess BMI from a life-course perspective to reduce RCC risk.
Data from Reproductive Factors in the Risk of Bladder Cancer and Upper Urinary Tract Cancer: The Japan Public Health Center-Based Prospective Study
Authors: Minami Tetsuji , Inoue Manami , Yamaji Taiki , Iwasaki Motoki , Tsugane Shoichiro , Sawada Norie
Published: November 2023

AbstractBackground:
Reproductive factors are hypothesized to play a role in the incidence of bladder cancer and upper urinary tract cancer (UUTC, together, urothelial cancer). However, evidence regarding these associations is limited, particularly in Asian populations.
Methods:
We analyzed data from 55,882 females ages 40 to 69 years, and performed Cox proportional hazards regression analyses with three types of adjustment, namely age; reproductive factor of interest and covariates in addition to age (conventional model); and other reproductive factors in addition to the multivariable adjusted model (reproductive model).
Results:
During an average of 20.2 years of follow-up, 194 urothelial cancer cases (145 bladder cancer cases and 49 UUTC cases) were identified. Early age at natural menopause (<44 years, compared with 49–51 years) increased bladder cancer risk in the reproductive model (HR, 2.09; 95% CI, 1.04–4.20). An association between urothelial cancer/bladder cancer and age at menopause, including both natural and surgical/induced, was significant in the reproductive model (HR, 1.74; 95% CI, 1.09–2.77; and HR, 1.94; 95% CI, 1.15–3.28, respectively). Early age at natural menopause was suggested to increase urothelial cancer risk in the reproductive model (HR, 1.78; 95% CI, 0.93–3.42).
Conclusions:
Our findings suggest a significant association between age at menopause and incidence of urothelial cancer/bladder cancer among Asian populations. This study aids understanding the role of reproductive factors in urothelial cancer/bladder cancer incidence.
Impact:
In Japanese populations, age at menopause is suggested to be associated with urothelial cancer/bladder cancer incidence, especially regarding early natural menopause.
Supplemental Table S1 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Authors: McKay-Corkum Grace B. , Collins Victor J. , Yeung Choh , Ito Takeshi , Issaq Sameer H. , Holland David , Vulikh Ksenia , Zhang Yiping , Lee Unsun , Lei Haiyan , Mendoza Arnulfo , Shern Jack F. , Yohe Marielle E. , Yamamoto Kazutoshi , Wilson Kelli , Ji Jiuping , Karim Baktiar O. , Thomas Craig J. , Krishna Murali C. , Neckers Leonard M. , Heske Christine M.
Published: November 2023

Supplemental Table S1: Molecular features of RMS cell lines
Supplemental Methods 1 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Authors: McKay-Corkum Grace B. , Collins Victor J. , Yeung Choh , Ito Takeshi , Issaq Sameer H. , Holland David , Vulikh Ksenia , Zhang Yiping , Lee Unsun , Lei Haiyan , Mendoza Arnulfo , Shern Jack F. , Yohe Marielle E. , Yamamoto Kazutoshi , Wilson Kelli , Ji Jiuping , Karim Baktiar O. , Thomas Craig J. , Krishna Murali C. , Neckers Leonard M. , Heske Christine M.
Published: November 2023

Supplemental Methods
Supplementary Figure S2 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

List of patients and samples included in the analysis of acquired resistance
Supplementary Figure S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

CONSORT flow diagram of patients enrolled in the study
Supplementary Data S9 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Supplementary Data 9 describes the results from OncoSIgnal analysis.
Supplemental Figure S4 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Authors: McKay-Corkum Grace B. , Collins Victor J. , Yeung Choh , Ito Takeshi , Issaq Sameer H. , Holland David , Vulikh Ksenia , Zhang Yiping , Lee Unsun , Lei Haiyan , Mendoza Arnulfo , Shern Jack F. , Yohe Marielle E. , Yamamoto Kazutoshi , Wilson Kelli , Ji Jiuping , Karim Baktiar O. , Thomas Craig J. , Krishna Murali C. , Neckers Leonard M. , Heske Christine M.
Published: November 2023

Supplemental Figure S4: Effect of OT-82 on mechanism of RMS cell death
Supplementary Data S7 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Supplementary Data 7 describes the molecular features associated with response and primary resistance to ARPI.
Supplemental Figure S2 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Authors: McKay-Corkum Grace B. , Collins Victor J. , Yeung Choh , Ito Takeshi , Issaq Sameer H. , Holland David , Vulikh Ksenia , Zhang Yiping , Lee Unsun , Lei Haiyan , Mendoza Arnulfo , Shern Jack F. , Yohe Marielle E. , Yamamoto Kazutoshi , Wilson Kelli , Ji Jiuping , Karim Baktiar O. , Thomas Craig J. , Krishna Murali C. , Neckers Leonard M. , Heske Christine M.
Published: November 2023

Supplemental Figure S2: Endpoint tumor volumes and mouse weights for in vivo experiments using OT-82 in RMS models
Supplementary Data S5 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Supplementary Data 5 describes the germline mutations in DNA repair genes in patients enrolled in the study.
Supplemental Figure S1 from Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
Authors: McKay-Corkum Grace B. , Collins Victor J. , Yeung Choh , Ito Takeshi , Issaq Sameer H. , Holland David , Vulikh Ksenia , Zhang Yiping , Lee Unsun , Lei Haiyan , Mendoza Arnulfo , Shern Jack F. , Yohe Marielle E. , Yamamoto Kazutoshi , Wilson Kelli , Ji Jiuping , Karim Baktiar O. , Thomas Craig J. , Krishna Murali C. , Neckers Leonard M. , Heske Christine M.
Published: November 2023

Supplemental Figure S1: Effect of NAMPT inhibition and evaluation of NAD+ producing enzymes in a panel of molecularly diverse RMS cell lines and models
Supplementary Data S2 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Supplementary Data 2 reports the DNA alterations from WES.
Supplementary Data S12 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Authors: Menssouri Naoual , Poiraudeau Loïc , Helissey Carole , Bigot Ludovic , Sabio Jonathan , Ibrahim Tony , Pobel Cédric , Nicotra Claudio , Ngo-Camus Maud , Lacroix Ludovic , Rouleau Etienne , Tselikas Lambros , Chauchereau Anne , Blanc-Durand Félix , Bernard-Tessier Alice , Patrikidou Anna , Naoun Natacha , Flippot Ronan , Colomba Emeline , Fuerea Alina , Albiges Laurence , Lavaud Pernelle , van de Wiel Paul , den Biezen Eveline , Wesseling-Rozendaal Yvonne , Ponce Santiago , Michiels Stefan , Massard Christophe , Gautheret Daniel , Barlesi Fabrice , André Fabrice , Besse Benjamin , Scoazec Jean-Yves , Friboulet Luc , Fizazi Karim , Loriot Yohann
Published: November 2023

Supplementary data 12 describes the GSEA analysis of resistant samples vs baseline samples from patients with acquired resistance
Supplementary Table S3 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Table 3. Adverse events with an incidence of
≥10% in any treatment arm.
Supplementary Figure S4 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Figure 4. Swimlane plots of treatment and clinical response.
Supplementary Figure S3 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Figure 3. Evaluation of pharmacodynamic biomarkers over time in the atezolizumab plus tocilizumab arm.
Supplementary Figure S2 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Figure 2. Relationship between plasma IL-6 levels and clinical response in the atezolizumab plus tocilizumab arm
Supplementary Figure S1 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Authors: Drakaki Alexandra , Powles Thomas , Bamias Aristotelis , Martin-Liberal Juan , Shin Sang Joon , Friedlander Terence , Tosi Diego , Park Chandler , Gomez-Roca Carlos , Joly Lobbedez Florence , Castellano Daniel , Morales-Barrera Rafael , Moreno-Candilejo Irene , Fléchon Aude , Yuen Kobe , Rishipathak Deepali , DuPree Kelly , Young Fiona , Michielin Francesca , Shemesh Colby S. , Steinberg Elizabeth E. , Williams Patrick , Lee Jae Lyun
Published: November 2023

Supplementary Figure 1. MORPHEUS-UC study design and timing
Supplementary Figure S7 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S7. Overview of average expression and fraction positives per cell type, timepoint and treatment condition for cytokines that are differentially expressed in neutrophils, monocytes, pDC, cDC, B cells, CD4+ T cells, CD8+ T cells, MAIT cells and/or NK cells treatment vs. control any timepoint. The untreated condition corresponds to the pooled baseline samples and incubation control samples. Mean of n= 4 donors (baseline, and 20 hrs) and n=2 donors (2 hrs, 4 hrs and 6 hrs).
Supplementary Table S3 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Table S3. Number of patients experiencing adverse events. Only those toxicities experienced while on the trial are presented in the table. Toxicities during the pre-study stage of the trial, for example, that were present before participants begin intervention were not included. Should a patient experience an adverse event more than once, the patient is only counted once at the highest grade for that adverse event.
Supplementary Figure S13 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S13. A. 3D in vitro experimental setup. Human PBMCs and SU-DHL-8 tumor cells were co-cultured in a ratio of 5:1 and treated with 0.01 nM CD20-TCB in the presence or absence of 5 μg/mL adalimumab for 24 hrs. Supernatant from the co-cultures was transferred to the bottom channel of the Mimetas OrganoPlate®. PBMCs derived from the same donor as in the co-cultures, are fluorescently labeled and seeded in the upper channel of the Mimetas OrganoPlate®, where endothelial tubules have been previously formed. Mimetas OrganoPlate® are then imaged with the Operetta System to quantify fluorescent cell transmigration at 24 hrs. B. Shown is the cell migration towards cytokine-rich supernatants in the Mimetas OrganoPlate®. TNF-α pretreatment of the endothelial tubule is a positive control. Means of technical replicates from 2 independent experiment +/- SD with ****p<0.0001, **p<0.001 by 2 way ANOVA.
Supplementary Figure S7 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Figure S7. Pearson correlation coefficient matrix analyses. Heatmap shows correlations among VO2peak, BMI, PGs, and immune cell types.
Supplementary Figure S10 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies
Authors: Leclercq-Cohen Gabrielle , Steinhoff Nathalie , Albertí Servera Llucia , Nassiri Sina , Danilin Sabrina , Piccione Emily , Yángüez Emilio , Hüsser Tamara , Herter Sylvia , Schmeing Stephan , Gerber Petra , Schwalie Petra , Sam Johannes , Briner Stefanie , Jenni Sylvia , Bianchi Roberta , Biehl Marlene , Cremasco Floriana , Apostolopoulou Katerina , Haegel Hélène , Klein Christian , Umaña Pablo , Bacac Marina
Published: November 2023

Supplementary Figure S10. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform
Supplementary Figure S6 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Figure S6. Deconvolution of immune cell types by CIBERSORT. Changes in deconvoluted immune cell type proportions derived from mRNAseq data are shown after twelve months of follow-up in the usual care
(N=6) and exercise (N=9) groups using CIBERSORT. No significant changes in immune cell types were observed, though CD8+ T cells were non-statistically significantly higher in the exercise group (two-tail Wilcoxon signed-rank test).
Supplementary Figure S5 from Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome
Authors: Deng Nan , Reyes-Uribe Laura , Fahrmann Johannes F. , Thoman Whittney S. , Munsell Mark F. , Dennison Jennifer B. , Murage Eunice , Wu Ranran , Hawk Ernest T. , Thirumurthi Selvi , Lynch Patrick M. , Dieli-Conwright Christina M. , Lazar Alexander J. , Jindal Sonali , Chu Khoi , Chelvanambi Manoj , Basen-Engquist Karen , Li Yisheng , Wargo Jennifer A. , McAllister Florencia , Allison James P. , Sharma Padmanee , Sinha Krishna M. , Hanash Samir , Gilchrist Susan C. , Vilar Eduardo
Published: November 2023

Figure S5. (A) Gene Set Enrichment Analysis (GSEA) of BIOCARTA IL-6 pathway; (B) Gene set of IL-6-stimulated cell cultures; (C) Gene set in IL-6-deprived cell cultures. GSEA was performed by 1000
permutations. The maximum and minimum sizes for gene sets were 500 and 15, respectively. The y-axis
represents the enrichment score (ES) and the x-axis lists the ranked genes by fold change. Vertical black
lines on the x-axis represent the genes in gene sets. The green line connects points of ES and genes. ES is the maximum deviation from zero as calculated for each gene going down the ranked list and represents the degree of over-representation of a gene set at the top or the bottom of the ranked gene list.
The P-value and ES are labeled at the top of the figure. The peak towards to left of the x-axis suggests a positive enrichment of the target gene set and vice versa.
Supplementary Table S5 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Authors: Casanova Michela , Bautista Francisco , Campbell-Hewson Quentin , Makin Guy , Marshall Lynley V. , Verschuur Arnauld C. , Cañete Nieto Adela , Corradini Nadège , Ploeger Bart A. , Brennan Barbara J. , Mueller Udo , Zebger-Gong Hong , Chung John W. , Geoerger Birgit
Published: November 2023

Table showing the representativeness of study participants
Supplementary Table S3 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Authors: Casanova Michela , Bautista Francisco , Campbell-Hewson Quentin , Makin Guy , Marshall Lynley V. , Verschuur Arnauld C. , Cañete Nieto Adela , Corradini Nadège , Ploeger Bart A. , Brennan Barbara J. , Mueller Udo , Zebger-Gong Hong , Chung John W. , Geoerger Birgit
Published: November 2023

Table of AEs potentially related to VI
Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Thummalapalli Rohit , Ricciuti Biagio , Bandlamudi Chaitanya , Muldoon Daniel , Rizvi Hira , Elkrief Arielle , Luo Jia , Alessi Joao V. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Hong Lingzhi , Zhang Jianjun , Heymach John V. , Gibbons Don L. , Plodkowski Andrew J. , Ravichandran Vignesh , Donoghue Mark T.A. , Vanderbilt Chad , Ladanyi Marc , Rudin Charles M. , Kris Mark G. , Riely Gregory J. , Chaft Jamie E. , Hellmann Matthew D. , Vokes Natalie I. , Awad Mark M. , Schoenfeld Adam J.
Published: November 2023

Frequencies of alterations in individual genes among non-squamous patient groups stratified by TMB z-score.
Supplementary Figure S3 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Authors: Casanova Michela , Bautista Francisco , Campbell-Hewson Quentin , Makin Guy , Marshall Lynley V. , Verschuur Arnauld C. , Cañete Nieto Adela , Corradini Nadège , Ploeger Bart A. , Brennan Barbara J. , Mueller Udo , Zebger-Gong Hong , Chung John W. , Geoerger Birgit
Published: November 2023

Distribution of individual clearance of irinotecan and its active metabolite SN-38.
Supplementary Table S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Thummalapalli Rohit , Ricciuti Biagio , Bandlamudi Chaitanya , Muldoon Daniel , Rizvi Hira , Elkrief Arielle , Luo Jia , Alessi Joao V. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Hong Lingzhi , Zhang Jianjun , Heymach John V. , Gibbons Don L. , Plodkowski Andrew J. , Ravichandran Vignesh , Donoghue Mark T.A. , Vanderbilt Chad , Ladanyi Marc , Rudin Charles M. , Kris Mark G. , Riely Gregory J. , Chaft Jamie E. , Hellmann Matthew D. , Vokes Natalie I. , Awad Mark M. , Schoenfeld Adam J.
Published: November 2023

List of PD-L1 antibodies used at each site and in the combined cohort.
Supplementary Data S1 from Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
Authors: Casanova Michela , Bautista Francisco , Campbell-Hewson Quentin , Makin Guy , Marshall Lynley V. , Verschuur Arnauld C. , Cañete Nieto Adela , Corradini Nadège , Ploeger Bart A. , Brennan Barbara J. , Mueller Udo , Zebger-Gong Hong , Chung John W. , Geoerger Birgit
Published: November 2023

Supplementary methods
Supplementary Figure S1 from ATM-Inhibitor AZD1390 Is a Radiosensitizer for Breast Cancer CNS Metastasis
Authors: Tew Ben Yi , Kalfa Alex J. , Yang Zeyi , Hurth Kyle M. , Simon Thomas , Abnoosian Eric , Durant Stephen T. , Hamerlik Petra , Salhia Bodour
Published: November 2023

Supplemental Figure 1. Immunochemistry (IHC) staining of γH2AX at experimental endpoint
Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Thummalapalli Rohit , Ricciuti Biagio , Bandlamudi Chaitanya , Muldoon Daniel , Rizvi Hira , Elkrief Arielle , Luo Jia , Alessi Joao V. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Hong Lingzhi , Zhang Jianjun , Heymach John V. , Gibbons Don L. , Plodkowski Andrew J. , Ravichandran Vignesh , Donoghue Mark T.A. , Vanderbilt Chad , Ladanyi Marc , Rudin Charles M. , Kris Mark G. , Riely Gregory J. , Chaft Jamie E. , Hellmann Matthew D. , Vokes Natalie I. , Awad Mark M. , Schoenfeld Adam J.
Published: November 2023

Genomic features of patients with long-term response (LTR) compared to short term response (STR), non-LTR, and progressive disease (PD) among patients with TMB z-score ≥ 0.
Supplementary Table S2 from Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies
Authors: Senapati Jayastu , Fiskus Warren C. , Daver Naval , Wilson Nathaniel R. , Ravandi Farhad , Garcia-Manero Guillermo , Kadia Tapan , DiNardo Courtney D. , Jabbour Elias , Burger Jan , Short Nicholas J. , Alvarado Yesid , Jain Nitin , Masarova Lucia , Issa Ghayas C. , Qiao Wei , Khoury Joseph D. , Pierce Sherry , Miller Darla , Sasaki Koji , Konopleva Marina , Bhalla Kapil N. , Borthakur Gautam , Pemmaraju Naveen
Published: November 2023

Hepatic adverse events
Supplementary Table S9 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
Authors: Geng Chuandong , Zhang Man-Chao , Manyam Ganiraju C. , Vykoukal Jody V. , Fahrmann Johannes F. , Peng Shan , Wu Cheng , Park Sanghee , Kondraganti Shakuntala , Wang Daoqi , Robinson Brian D. , Loda Massimo , Barbieri Christopher E. , Yap Timothy A. , Corn Paul G. , Hanash Samir , Broom Bradley M. , Pilié Patrick G. , Thompson Timothy C.
Published: November 2023

Supplementary Table S9. Quantification of each protein-specific band normalized to vinculin (Dox-inducible C4-2b–derived models, Fig. 4D, upper panel).
Supplementary Table S8 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth Suppression
Authors: Geng Chuandong , Zhang Man-Chao , Manyam Ganiraju C. , Vykoukal Jody V. , Fahrmann Johannes F. , Peng Shan , Wu Cheng , Park Sanghee , Kondraganti Shakuntala , Wang Daoqi , Robinson Brian D. , Loda Massimo , Barbieri Christopher E. , Yap Timothy A. , Corn Paul G. , Hanash Samir , Broom Bradley M. , Pilié Patrick G. , Thompson Timothy C.
Published: November 2023

Supplementary Table S8. Quantification of each protein-specific band normalized to vinculin (Dox-inducible RM-1-BM– and C4-2b–derived models, Fig. 3A, 3B).